Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CRMD
Strong BuyFLAGCorMedix Inc. · Healthcare · United States · $647M · Avg Vol: $11M/d
CorMedix reached profitability after the approval and launch of its catheter lock solution, which explains the strong quality and value scores. The company previously received multiple FDA complete response letters for this product before approval, and its economics now rest on a single commercial asset with a short revenue history. No current fraud, restatement or distress event is known, so the default applies rather than a removal.
COMPANY DESCRIPTION
CorMedix Inc. is a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases, particularly catheter-related infections. Its lead product candidate, DefenCath, aims to provide a novel antimicrobial solution for hemodialysis catheters, positioning the company to address a significant unmet medical need upon regulatory approval.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 65.4K | 0 | 43.5M | 311.7M | 1582.8% | 462.2M | 337.1M | 286.5M | -4.1% |
| EPS | -0.74 | -0.91 | -0.30 | 2.25 | — | 2.18 | — | — | — |
| Shares | 42.8M | 54.9M | 64.4M | 79.3M | +85.1% | 77.9M | — | — | — |
| Debt | 0.8M | 0.7M | 0.5M | 148.9M | 470.4% | 147.5M | — | — | — |
| Equity | 55.1M | 70.1M | 84.7M | 405.3M | 94.5% | — | — | — | — |
| Op CF | -24.4M | -38.4M | -50.6M | 175.0M | — | 253.9M | — | — | — |
| Inv CF | -3.7M | -17.1M | 21.2M | -308.4M | — | — | — | — | — |
| Fin CF | 17.9M | 55.9M | 26.3M | 238.5M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CRMD are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CRMD | CorMedix Inc.(you) | $647M | 98 | Strong Buy |
| RIGL | Rigel Pharmaceuticals, Inc. | $868M | 99 | Strong Buy |
| PBYI | Puma Biotechnology, Inc. | $468M | 99 | Strong Buy |
| ZVRA | Zevra Therapeutics, Inc. | $687M | 87 | Strong Buy |
| QTTB | Q32 Bio Inc. | $447M | 88 | Strong Buy |
| 1521.HK | Frontage Holdings Corporation | $310M | 92 | Strong Buy |
| INVA | Innoviva, Inc. | $1.5B | 93 | Strong Buy |
| ABUS | Arbutus Biopharma Corporation | $1.0B | 84 | Strong Buy |
| PLX | Protalix BioTherapeutics, Inc. | $205M | 97 | Strong Buy |
| AGEN | Agenus Inc. | $345M | 84 | Strong Buy |
Peer medians: ROE -25.9% · P/E 29.6x · Gross margin 58.7%